Chest
Clinical InvestigationsBronchitisCosts of Chronic Bronchitis and COPDa: A 1-Year Follow-up Study
Section snippets
Study Design
This pharmacoeconomic analysis was conducted with data derived from the follow-up of a cohort of patients included in a study on acute exacerbations of chronic bronchitis and COPD. Full details of the study methodology and patient selection are presented elsewhere.1112 A brief summary of the design is presented here. Two thousand four hundred fourteen patients with a diagnosis of chronic bronchitis consistent with American Thoracic Society (ATS) recommendations13 were initially recruited.
Results
Initially, 2,414 individuals with chronic bronchitis or COPD were recruited. Eighty-four patients (3.4%) required hospitalization for the first exacerbation and were subsequently followed up in the hospital; thus, they were not available for follow-up in primary care, leaving 2,330 patients available for the second phase of the study. A total of 1,510 patients (65%) completed the 12-month follow-up and formed the study population. No significant differences were observed between patients who
Discussion
COPD represents a great health-care burden in developed countries. However, few studies have been aimed at quantifying the real burden of the disease. Most of these studies are estimates based on administrative and population data and use a prevalence-based cost-of-illness approach,5678 others use data from health-care databases,9 and one study10 identified a group of patients with COPD from medical records and quantified retrospectively the use of medical resources in recent years. To our
Acknowledgment
The authors thank Irene Marimoén, BSc, for monitoring the study, Christine O’Hara for manuscript editing, and the primary care physicians who provided information on their patients.
References (26)
- et al.
Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): recruitment and field work [in Spanish]
Arch Bronconeumol
(1999) - et al.
Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands
Respir Med
(1999) - et al.
The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991
Respir Med
(2000) - et al.
Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema
Respir Med
(2000) - et al.
The cost of treating COPD in the United States
Chest
(2001) - et al.
Pharmacoeconomic evaluation of COPD
Chest
(2000) - et al.
Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD
Chest
(2002) - et al.
Physician perceptions and management of COPD
Chest
(1993) - et al.
Spirometry in primary care: the importance of quality assurance and the impact of spirometry workshops
Chest
(1999) - et al.
Treatment of chronic bronchitis and COPD in primary care [in Spanish]
Arch Bronconeumol
(1999)
The prevalence of COPD: using smoking rates to estimate disease frequency in the general population
Chest
Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice
Respir Med
Geographical variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study
Chest
Cited by (220)
Long term survival after admission for COPD exacerbation: A comparison with the general population
2018, Respiratory MedicineChronic bronchitis in relation to hospitalization and mortality over three decades
2017, Respiratory MedicineContribution of smoking change to 45-year trend in prevalence of chronic bronchitis in Finland
2023, Scandinavian Journal of Public HealthCost-effectiveness analysis of text messaging to support health advice for smoking cessation
2021, Cost Effectiveness and Resource Allocation
The DAFNE Group (Decisiones sobre Antibioticoterapia y Farmacoeconomiéa en la EPOC) is funded by Mercl Farma y Quiémica S.A.